Shook David sold $6K of LYEL
Shook David (Chief Medical Officer) sold 500 shares of Lyell Immunopharma, Inc. (LYEL) at $12.70 on 2026-09-10.
How this was made
The 30-second read
Why it matters
The sale is modest and unlikely to affect LYEL's stock price; serves as a routine disclosure.
Market read
Low relevance; routine insider transaction with minimal market impact.
What to watch
Potential upcoming clinical data releases could change insider behavior.
Background
Form 4 filing discloses insider transactions; used by traders to gauge insider sentiment.
Ticker impact
Chief Medical Officer Shook David sold 500 shares for $6,350 on 2026-09-10.
No significant impact; price likely unchanged.
Sale size is trivial relative to total holdings and market cap.
Market effects
Insider sale does not affect biotech sector outlook.
No regional market effect.
Limited global relevance.
Counterpoint
Even small insider sales can signal concerns; monitor for further disposals.
Key entities
- CompanyLyell Immunopharma, Inc.
Biotech firm developing therapies for liver disease.
- InsiderShook David
Chief Medical Officer of LYEL.